Liposomal Bupivacaine/Bupivacaine in RS Blocks vs. Ropivacaine in RS Blocks And Catheters
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The goal of this randomized clinical trial is to compare single shot rectus sheath blocks of
liposomal bupivacaine/bupivacaine mixture to bilateral rectus sheath catheters infused with
ropivacaine (standard of care at our facility) in patients undergoing vascular surgery with
an open mid-abdominal laparotomy incision. This study will examine the difference in the
highest, lowest, average, and current pain scores reported at the end of 24-48 postoperative
hours using the brief pain inventory-short form (BPI-SF).
Participants will be randomized to either receive a single dose of liposomal
bupivacaine/bupivacaine mixture intraoperatively at the end of surgery through bilateral
rectus sheath blocks (LB/B group) or to receive the standard of care ropivacaine
intraoperatively at the end of surgery through bilateral rectus sheath blocks with the
insertion of bilateral RS catheter for continuous ropivacaine infusion plus repeated daily
boluses (Catheter group; standard care). They will be assessed for a difference in
postoperative pain scores, opioid consumption, hospital and PACU length of stay, patient's
satisfaction, and quality of recovery. Additionally, we will examine the resources consumed
by each intervention, including the medication cost (ropivacaine vs. LB/bupivacaine mixture),
block and catheter supply, hospital length of stay, and anesthesia billing time.